"We Envision Growth Strategies Most Suited
to Your Business"

Autism Spectrum Disorder Therapeutics Market Worth USD 4,612.1 Million at 4.3% CAGR Forecast by 2026

August 22, 2019 | Healthcare

The Global Autism Spectrum Disorder Therapeutics Market will benefit from the increasing investment in the research and development of effective drugs. According to a report published by Fortune Business Insights, titled “Autism Spectrum Disorder Therapeutics Market: Global Market Analysis, Insights, and Forecast, 2018-2026,” the global market was valued at US$ 3,293.0 Mn in 2018. Fortune Business Insights has predicted that the autism spectrum disorder therapeutics market will reach US$ 4,612.1 Mn by 2026, thereby exhibiting a moderate CAGR of 4.3% in the forecast period (2019-2026).


Presence of Well-established Autism Treatment Centers to Favor Growth in North America 


In terms of geography, the overall autism spectrum disorder therapeutics market share is divided between Asia Pacific, the Middle East and Africa, North America, Europe, and Latin America. Amongst these, North America generated US$ 1,911.7 Mn in terms of global market revenue in 2018. The region is expected to retain its position during the forecast period.


This growth is attributed to the presence of prominent key players and the persistent investments in research and development activities that they are initiating in the region. Additionally, strategic collaborations, mergers, the existence of technologically advanced autism treatment centers for children, and favorable reimbursement policies are expected to propel the autism spectrum disorder therapeutics market growth in North America.


Asia Pacific, on the other hand, is projected to exhibit significant growth in the forthcoming years owing to the increasing incidence of autism spectrum disorder in emerging countries, such as India and China. This will result in a rise in the demand for advanced therapies for the treatment of autism spectrum disorder in developing countries.


Fortune Business Insights predicts that Europe will follow the footsteps of North America and will remain in the second position by generating high revenue. This will occur because of the increasing awareness programs regarding several available therapies that are essential for the treatment of autism spectrum disorder. The Middle East and Africa and Latin America will open their doors for new opportunities for the establishment of autism care centers. 


Increasing FDA Approval and Favorable Reimbursement Policies to Drive the Global Market


There is a rise in the prevalence of autism spectrum disorder across the globe. This, combined with an urgent requirement for treatment options and therapies, are likely to drive the global autism spectrum disorder market during the forecast period. Prominent key players, as well as numerous government organizations operating in the industry, are investing considerable sums in the development of therapies that would aid in treating autism spectrum disorder.  


The Halifax Group, an established private equity, based in Washington, for instance, announced in 2019 that it has completed its investment in ChanceLight Behavioral Health, Therapy & Education. ChanceLight is one of the most prominent providers of education solutions, behavioral therapy, and health for children as well as young adults.


Moreover, favorable reimbursement policies will boost growth of the global autism spectrum disorder therapeutics market. Also, day by day, the number of children diagnosed with autism is increasing rapidly. This, in turn, is causing a rise in the demand for applied behavioral analysis therapies for the treatment of autistic children who suffer from learning and physical disabilities.


The FDA has been approving the latest drugs that are developed by several key market players to manage autism spectrum disorder. This is further anticipated to propel the global autism spectrum market growth in the forecast period.


Fortune Business Insights has profiled some of the key market players operating in the global autism spectrum disorder therapeutics market. They are Applied Behavior Consultants, Allergan, Pfizer Inc., Q BioMed Inc, Fusion Autism Center, Center for Autism and Related Disorders, AstraZeneca, Hopebridge, LLC., Johnson & Johnson Services, Inc., Behavior Innovations, Eli Lilly and Company, Otsuka Holdings Co. Ltd., and other prominent market players.


Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/autism-spectrum-disorder-therapeutics-market-101207


The global autism spectrum disorder therapeutics market is segmented based on:






















ATTRIBUTE


  DETAILS

By Type




  • Autistic Disorder

  • Asperger Syndrome

  • Pervasive Developmental Disorder

  • Others



By Treatment Type




  • Communication & Behavioral Therapies

    • Applied behavior analysis (ABA)

    • Speech & Language Therapy

    • Occupational Therapy

    • Others



  • Drug Therapies

    • Antipsychotic Drugs

    • SSRIs

    • Stimulants

    • Sleep Medications

    • Others





By Geography




  • North America (U.S. and Canada)

  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico, and Rest of Latin America)

  • Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)


We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X